Alembic Pharmaceuticals shines on getting USFDA`s final nod for Diltiazem Hydrochloride Tablets
Alembic Pharmaceuticals is currently trading at Rs. 928.00, up by 25.20 points or 2.79% from its previous closing of Rs. 902.80 on the BSE.
The scrip opened at Rs. 919.00 and has touched a high and low of Rs. 928.95 and Rs. 911.50 respectively. So far 3191 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1122.40 on 06-Jan-2025 and a 52 week low of Rs. 725.60 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 930.70 and Rs. 900.00 respectively. The current market cap of the company is Rs. 18114.27 crore.
The promoters holding in the company stood at 69.74%, while Institutions and Non-Institutions held 20.35% and 9.92% respectively.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg, of Bausch Health US, LLC.
Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. The company has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA.
Alembic Pharmaceuticals (Alembic Pharma) is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.
